Today: 27 February 2026
Subscribe
Browse Category

NYSE:JNJ 22 December 2025 - 1 January 2026

Johnson & Johnson stock holds near $207 as New Year’s Day shuts U.S. markets — what to watch next

Johnson & Johnson stock holds near $207 as New Year’s Day shuts U.S. markets — what to watch next

Johnson & Johnson shares closed up 0.02% at $206.95 on Wednesday, ahead of the New Year’s Day market holiday. The company completed its $3.05 billion acquisition of Halda Therapeutics and plans to appeal a $1.5 billion talc verdict. Drugmakers are set to raise list prices on at least 350 medicines in 2026, Reuters reported. J&J’s fourth-quarter earnings call is set for Jan. 21.
1 January 2026
·
Johnson & Johnson stock ends 2025 steady as Halda deal closes and Barclays hikes target

Johnson & Johnson stock ends 2025 steady as Halda deal closes and Barclays hikes target

Johnson & Johnson closed its $3.05 billion acquisition of Halda Therapeutics, saying the deal will cut adjusted EPS by $0.20 between late 2025 and 2026. JNJ shares edged up 0.02% to $206.95 as the S&P 500 fell 0.74% on the year’s final trading day. Barclays raised its price target to $217, maintaining an Equal Weight rating. The company will discuss its 2026 outlook on Jan. 21.
1 January 2026
··
JNJ stock slips after hours as Johnson & Johnson closes $3.05B Halda Therapeutics deal

JNJ stock slips after hours as Johnson & Johnson closes $3.05B Halda Therapeutics deal

Johnson & Johnson closed its $3.05 billion cash acquisition of Halda Therapeutics, adding the RIPTAC oncology platform and lead prostate cancer program. Shares slipped 0.3% to $206.91 in after-hours trading. The company expects about $0.20 dilution to adjusted EPS, split between 2025 and 2026, and will discuss 2026 guidance on its Jan. 21 earnings call.
31 December 2025
··
JNJ stock today: J&J closes $3.05B Halda cancer deal, flags EPS hit — what’s next

JNJ stock today: J&J closes $3.05B Halda cancer deal, flags EPS hit — what’s next

Johnson & Johnson closed its $3.05 billion cash acquisition of Halda Therapeutics, a cancer drug developer, on Monday. The company said it expects about $0.20 in adjusted EPS dilution, split between the fourth quarter and 2026. JNJ shares ended down 0.02% at $207.56. Investors await the Jan. 21 earnings call for 2026 guidance.
30 December 2025
····
Johnson & Johnson stock (JNJ) holds near $208 as J&J halts eczema trial; what investors should watch before Monday’s open

Johnson & Johnson stock (JNJ) holds near $208 as J&J halts eczema trial; what investors should watch before Monday’s open

Johnson & Johnson has halted a Phase 2b trial of its experimental eczema drug JNJ-5939 after interim results failed to meet efficacy targets, though the therapy was well tolerated. The stock last traded near $207.63, slightly down before the market closed for the weekend. The New York Stock Exchange will reopen Monday.
28 December 2025
··
Johnson & Johnson Stock (JNJ) Update: Shares Hold Near $208 as Markets Close for the Weekend; Eczema Trial Halt, Pipeline Wins, and 2026 Outlook in Focus

Johnson & Johnson Stock (JNJ) Update: Shares Hold Near $208 as Markets Close for the Weekend; Eczema Trial Halt, Pipeline Wins, and 2026 Outlook in Focus

Johnson & Johnson shares closed at $207.63 Friday, down 0.07%, after the company halted a mid-stage trial of its eczema drug JNJ-5939 due to lack of efficacy. The drug was well-tolerated but failed to meet targets in interim analysis. JNJ’s market cap stands near $500 billion, with a 2.5% dividend yield. The stock traded at $207.86 after hours ahead of Monday’s market open.
27 December 2025
··
Healthcare Stocks Outlook: Year-End Rotation, J&J’s Eczema Setback, and Managed-Care Scrutiny Shape the Setup Before Monday’s Open

Healthcare Stocks Outlook: Year-End Rotation, J&J’s Eczema Setback, and Managed-Care Scrutiny Shape the Setup Before Monday’s Open

U.S. stock markets were closed Saturday after Wall Street ended Friday nearly flat; the Dow slipped 0.04%, S&P 500 fell 0.03%, and Nasdaq lost 0.09%. Large-cap healthcare stocks held steady, while biotech lagged. Johnson & Johnson halted a Phase 2 eczema drug trial after missing efficacy goals. Healthcare ETFs closed Friday with XLV at $156.05, XBI at $124.98, and IBB at $171.44.
27 December 2025
Johnson & Johnson (JNJ) Stock: What to Know Before the Market Opens on Dec. 26, 2025

Johnson & Johnson (JNJ) Stock: What to Know Before the Market Opens on Dec. 26, 2025

U.S. markets reopen Friday, Dec. 26, after the Christmas holiday. Johnson & Johnson shares last traded near $207.78, up 0.6% from the previous close, with recent sessions marked by low volume. The company faces renewed legal pressure after a Baltimore jury ordered it to pay over $1.5 billion in a talc case, with J&J planning to appeal. Over 67,000 talc-related lawsuits remain unresolved.
26 December 2025
·
Johnson & Johnson Stock After Hours Today (Dec. 25, 2025): JNJ Holds Near $208 — What to Know Before the Market Opens Dec. 26

Johnson & Johnson Stock After Hours Today (Dec. 25, 2025): JNJ Holds Near $208 — What to Know Before the Market Opens Dec. 26

Johnson & Johnson shares last closed at $207.78 on Dec. 24, up 0.97%, with after-hours trading nearly flat at $207.75 ahead of the Christmas market closure. The New York Stock Exchange was shut Dec. 25 and will reopen Dec. 26. J&J faces ongoing headline risk from talc litigation, including a recent $1.5 billion jury verdict in Baltimore. The company is appealing and disputes the claims.
25 December 2025
·
Johnson & Johnson Stock After the Bell Dec. 24, 2025: JNJ Holds Near $208 — Key News, Forecasts, and What to Watch Before the Next Market Open

Johnson & Johnson Stock After the Bell Dec. 24, 2025: JNJ Holds Near $208 — Key News, Forecasts, and What to Watch Before the Next Market Open

Johnson & Johnson shares closed up 0.95% at $207.78 in a shortened Christmas Eve session, with trading volume at 2.38 million shares. The move comes as a Baltimore jury ordered J&J to pay over $1.5 billion in a talc cancer case, which the company plans to appeal. U.S. markets closed early and will remain shut for Christmas Day.
24 December 2025
··
Johnson & Johnson Stock Today: JNJ Holds Near $207 on Dec. 24, 2025 as Talc Verdict, Drug-Price Pressure and Q4 Earnings Take Center Stage

Johnson & Johnson Stock Today: JNJ Holds Near $207 on Dec. 24, 2025 as Talc Verdict, Drug-Price Pressure and Q4 Earnings Take Center Stage

Johnson & Johnson traded near $207 per share in thin holiday trading Wednesday, keeping its market value around $500 billion. A Baltimore jury ordered the company to pay over $1.5 billion in a talc cancer case, the largest such verdict to date. J&J said it will appeal. U.S. markets close early at 1 p.m. ET for Christmas Eve.
24 December 2025
···
Johnson & Johnson Stock (JNJ) Slips After Record $1.5B Talc Verdict: News, Forecasts, and What to Watch Into 2026

Johnson & Johnson Stock (JNJ) Slips After Record $1.5B Talc Verdict: News, Forecasts, and What to Watch Into 2026

Johnson & Johnson shares fell 0.9% to $205.43 on Dec. 23 after a Baltimore jury ordered the company to pay over $1.5 billion in a talc cancer case, the largest single-plaintiff award in this litigation. J&J plans to appeal and maintains its talc products are safe. The company faces more than 67,000 talc-related lawsuits. Broader U.S. indexes closed modestly higher.
23 December 2025
··
Kenvue Stock (KVUE) News, Forecasts and Analysis for December 23, 2025: Deal Math, Legal Headlines, and What Investors Are Watching

Kenvue Stock (KVUE) News, Forecasts and Analysis for December 23, 2025: Deal Math, Legal Headlines, and What Investors Are Watching

A Baltimore jury ordered Johnson & Johnson and spinoff Kenvue to pay over $1.5 billion in a talc cancer case, with J&J saying it will appeal. Kenvue shares traded at $16.98, about $1.15 below the implied $18.12 merger value based on Kimberly-Clark’s price, reflecting deal risk. The acquisition is expected to close in the second half of 2026. J&J has said it will cover Kenvue’s talc liabilities.
23 December 2025
···
Johnson & Johnson (JNJ) Stock After Hours Today (Dec. 22, 2025): After-the-Bell Move, Key Headlines, and What to Watch Before Tuesday’s Open

Johnson & Johnson (JNJ) Stock After Hours Today (Dec. 22, 2025): After-the-Bell Move, Key Headlines, and What to Watch Before Tuesday’s Open

Johnson & Johnson closed Monday at $207.32, up 0.46%, with after-hours trading showing little movement on light volume. Investors tracked Washington’s drug-pricing push and new talc-litigation updates. Hedge funds turned more cautious on healthcare stocks, according to Reuters. NYSE will close early Wednesday and remain shut Thursday for Christmas.
23 December 2025
·
Johnson & Johnson Stock (JNJ) News Today: Latest Updates, Analyst Forecasts, and What Could Move Shares Next (Dec. 22, 2025)

Johnson & Johnson Stock (JNJ) News Today: Latest Updates, Analyst Forecasts, and What Could Move Shares Next (Dec. 22, 2025)

Johnson & Johnson shares traded at $206.63 Monday after the European Commission approved TREMFYA for pediatric psoriasis, marking its first IL-23 inhibitor indication in children. The company also secured recent FDA approvals for RYBREVANT FASPRO in lung cancer and TRUFILL n-BCA for chronic subdural hematoma. Ongoing talc litigation continues to affect investor sentiment.
22 December 2025
·
1 … 3 4 5 6 7 8
Go toTop